ID   CSK22_HUMAN             Reviewed;         350 AA.
AC   P19784;
DT   01-FEB-1991, integrated into UniProtKB/Swiss-Prot.
DT   01-FEB-1991, sequence version 1.
DT   12-OCT-2022, entry version 222.
DE   RecName: Full=Casein kinase II subunit alpha';
DE            Short=CK II alpha';
DE            EC=2.7.11.1;
GN   Name=CSNK2A2; Synonyms=CK2A2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=2174700; DOI=10.1021/bi00488a034;
RA   Lozeman F.J., Litchfield D.W., Piening C., Takio K., Walsh K.A.,
RA   Krebs E.G.;
RT   "Isolation and characterization of human cDNA clones encoding the alpha and
RT   the alpha' subunits of casein kinase II.";
RL   Biochemistry 29:8436-8447(1990).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Ovary;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [3]
RP   FUNCTION, AND INTERACTION WITH SSRP1 AND SUPT16H.
RX   PubMed=11239457; DOI=10.1016/s1097-2765(01)00176-9;
RA   Keller D.M., Zeng X., Wang Y., Zhang Q.H., Kapoor M., Shu H., Goodman R.,
RA   Lozano G., Zhao Y., Lu H.;
RT   "A DNA damage-induced p53 serine 392 kinase complex contains CK2, hSpt16,
RT   and SSRP1.";
RL   Mol. Cell 7:283-292(2001).
RN   [4]
RP   FUNCTION IN CELL CYCLE.
RX   PubMed=11704824; DOI=10.1038/sj.onc.1204894;
RA   Sayed M., Pelech S., Wong C., Marotta A., Salh B.;
RT   "Protein kinase CK2 is involved in G2 arrest and apoptosis following
RT   spindle damage in epithelial cells.";
RL   Oncogene 20:6994-7005(2001).
RN   [5]
RP   INTERACTION WITH SSRP1 AND SUPT16H.
RX   PubMed=12393879; DOI=10.1074/jbc.m209820200;
RA   Keller D.M., Lu H.;
RT   "p53 serine 392 phosphorylation increases after UV through induction of the
RT   assembly of the CK2.hSPT16.SSRP1 complex.";
RL   J. Biol. Chem. 277:50206-50213(2002).
RN   [6]
RP   FUNCTION IN APOPTOSIS.
RX   PubMed=16193064; DOI=10.1038/sj.emboj.7600827;
RA   Shin S., Lee Y., Kim W., Ko H., Choi H., Kim K.;
RT   "Caspase-2 primes cancer cells for TRAIL-mediated apoptosis by processing
RT   procaspase-8.";
RL   EMBO J. 24:3532-3542(2005).
RN   [7]
RP   REVIEW ON FUNCTION.
RX   PubMed=12631575; DOI=10.1096/fj.02-0473rev;
RA   Meggio F., Pinna L.A.;
RT   "One-thousand-and-one substrates of protein kinase CK2?";
RL   FASEB J. 17:349-368(2003).
RN   [8]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-18; SER-21 AND SER-288, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of the
RT   kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [9]
RP   REVIEW ON STRUCTURE.
RX   PubMed=19387553; DOI=10.1007/s00018-009-9149-8;
RA   Niefind K., Raaf J., Issinger O.G.;
RT   "Protein kinase CK2 in health and disease: Protein kinase CK2: from
RT   structures to insights.";
RL   Cell. Mol. Life Sci. 66:1800-1816(2009).
RN   [10]
RP   REVIEW ON FUNCTION.
RX   PubMed=19387552; DOI=10.1007/s00018-009-9150-2;
RA   St-Denis N.A., Litchfield D.W.;
RT   "Protein kinase CK2 in health and disease: From birth to death: the role of
RT   protein kinase CK2 in the regulation of cell proliferation and survival.";
RL   Cell. Mol. Life Sci. 66:1817-1829(2009).
RN   [11]
RP   REVIEW ON FUNCTION.
RX   PubMed=19387551; DOI=10.1007/s00018-009-9151-1;
RA   Filhol O., Cochet C.;
RT   "Protein kinase CK2 in health and disease: Cellular functions of protein
RT   kinase CK2: a dynamic affair.";
RL   Cell. Mol. Life Sci. 66:1830-1839(2009).
RN   [12]
RP   REVIEW ON FUNCTION IN REGULATION OF HSP90.
RX   PubMed=19387550; DOI=10.1007/s00018-009-9152-0;
RA   Miyata Y.;
RT   "Protein kinase CK2 in health and disease: CK2: the kinase controlling the
RT   Hsp90 chaperone machinery.";
RL   Cell. Mol. Life Sci. 66:1840-1849(2009).
RN   [13]
RP   REVIEW ON FUNCTION IN WNT SIGNALING.
RX   PubMed=19387549; DOI=10.1007/s00018-009-9153-z;
RA   Dominguez I., Sonenshein G.E., Seldin D.C.;
RT   "Protein kinase CK2 in health and disease: CK2 and its role in Wnt and NF-
RT   kappaB signaling: linking development and cancer.";
RL   Cell. Mol. Life Sci. 66:1850-1857(2009).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-13; SER-18; SER-21 AND
RP   SER-288, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [15]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-97, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C.,
RA   Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [16]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-18, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [18]
RP   X-RAY CRYSTALLOGRAPHY (3.20 ANGSTROMS) OF 1-334 IN COMPLEX WITH INHIBITOR.
RX   PubMed=19193990; DOI=10.1107/s1744309108043194;
RA   Nakaniwa T., Kinoshita T., Sekiguchi Y., Tada T., Nakanishi I., Kitaura K.,
RA   Suzuki Y., Ohno H., Hirasawa A., Tsujimoto G.;
RT   "Structure of human protein kinase CK2 alpha 2 with a potent indazole-
RT   derivative inhibitor.";
RL   Acta Crystallogr. F 65:75-79(2009).
RN   [19]
RP   X-RAY CRYSTALLOGRAPHY (2.00 ANGSTROMS).
RX   PubMed=21241709; DOI=10.1016/j.jmb.2011.01.020;
RA   Bischoff N., Olsen B., Raaf J., Bretner M., Issinger O.G., Niefind K.;
RT   "Structure of the human protein kinase CK2 catalytic subunit CK2alpha' and
RT   interaction thermodynamics with the regulatory subunit CK2beta.";
RL   J. Mol. Biol. 407:1-12(2011).
RN   [20]
RP   VARIANT [LARGE SCALE ANALYSIS] ALA-188.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Catalytic subunit of a constitutively active
CC       serine/threonine-protein kinase complex that phosphorylates a large
CC       number of substrates containing acidic residues C-terminal to the
CC       phosphorylated serine or threonine. Regulates numerous cellular
CC       processes, such as cell cycle progression, apoptosis and transcription,
CC       as well as viral infection. May act as a regulatory node which
CC       integrates and coordinates numerous signals leading to an appropriate
CC       cellular response. During mitosis, functions as a component of the
CC       p53/TP53-dependent spindle assembly checkpoint (SAC) that maintains
CC       cyclin-B-CDK1 activity and G2 arrest in response to spindle damage.
CC       Also required for p53/TP53-mediated apoptosis, phosphorylating 'Ser-
CC       392' of p53/TP53 following UV irradiation. Can also negatively regulate
CC       apoptosis. Phosphorylates the caspases CASP9 and CASP2 and the
CC       apoptotic regulator NOL3. Phosphorylation protects CASP9 from cleavage
CC       and activation by CASP8, and inhibits the dimerization of CASP2 and
CC       activation of CASP8. Regulates transcription by direct phosphorylation
CC       of RNA polymerases I, II, III and IV. Also phosphorylates and regulates
CC       numerous transcription factors including NF-kappa-B, STAT1, CREB1,
CC       IRF1, IRF2, ATF1, SRF, MAX, JUN, FOS, MYC and MYB. Phosphorylates Hsp90
CC       and its co-chaperones FKBP4 and CDC37, which is essential for chaperone
CC       function. Regulates Wnt signaling by phosphorylating CTNNB1 and the
CC       transcription factor LEF1. Acts as an ectokinase that phosphorylates
CC       several extracellular proteins. During viral infection, phosphorylates
CC       various proteins involved in the viral life cycles of EBV, HSV, HBV,
CC       HCV, HIV, CMV and HPV. {ECO:0000269|PubMed:11239457,
CC       ECO:0000269|PubMed:11704824, ECO:0000269|PubMed:16193064}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1;
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
CC         Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.11.1;
CC   -!- ACTIVITY REGULATION: Constitutively active protein kinase whose
CC       activity is not directly affected by phosphorylation. Seems to be
CC       regulated by level of expression and localization (By similarity).
CC       {ECO:0000250}.
CC   -!- SUBUNIT: Heterotetramer composed of two catalytic subunits (alpha chain
CC       and/or alpha' chain) and two regulatory subunits (beta chains). The
CC       tetramer can exist as a combination of 2 alpha/2 beta, 2 alpha'/2 beta
CC       or 1 alpha/1 alpha'/2 beta subunits. Also part of a CK2-SPT16-SSRP1
CC       complex composed of SSRP1, SUPT16H, CSNK2A1, CSNK2A2 and CSNK2B, which
CC       forms following UV irradiation (PubMed:11239457, PubMed:12393879).
CC       Interacts with CSNKA2IP (via C-terminus) (By similarity). Interacts
CC       with SIRT6; preventing CSNK2A2 localization to the nucleus (By
CC       similarity). Interacts with RNPS1. {ECO:0000250|UniProtKB:O54833,
CC       ECO:0000269|PubMed:11239457, ECO:0000269|PubMed:12393879,
CC       ECO:0000269|PubMed:19193990}.
CC   -!- INTERACTION:
CC       P19784; P68400: CSNK2A1; NbExp=10; IntAct=EBI-347451, EBI-347804;
CC       P19784; P67870: CSNK2B; NbExp=14; IntAct=EBI-347451, EBI-348169;
CC       P19784; O60282: KIF5C; NbExp=4; IntAct=EBI-347451, EBI-717170;
CC       P19784; Q9NRD5: PICK1; NbExp=5; IntAct=EBI-347451, EBI-79165;
CC       P19784; Q8WV44: TRIM41; NbExp=7; IntAct=EBI-347451, EBI-725997;
CC       P19784; Q9BS34: ZNF670; NbExp=4; IntAct=EBI-347451, EBI-745276;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000250|UniProtKB:O54833}. Cytoplasm
CC       {ECO:0000250|UniProtKB:O54833}. Note=Interaction with SIRT6 prevents
CC       translocation into the nucleus. {ECO:0000250|UniProtKB:O54833}.
CC   -!- MISCELLANEOUS: Can use both ATP and GTP as phosphoryl donors.
CC       Phosphorylation by casein kinase 2 has been estimated to represent up
CC       to one quarter of the eukaryotic phosphoproteome.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Ser/Thr protein
CC       kinase family. CK2 subfamily. {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M55268; AAA51548.1; -; mRNA.
DR   EMBL; BC008812; AAH08812.1; -; mRNA.
DR   CCDS; CCDS10794.1; -.
DR   PIR; B35838; B35838.
DR   RefSeq; NP_001887.1; NM_001896.2.
DR   PDB; 3E3B; X-ray; 3.20 A; X=1-334.
DR   PDB; 3OFM; X-ray; 2.00 A; A=1-350.
DR   PDB; 3U87; X-ray; 2.90 A; A/B=327-350.
DR   PDB; 5M4U; X-ray; 2.19 A; A=1-350.
DR   PDB; 5M56; X-ray; 2.24 A; A/B=1-350.
DR   PDB; 5OOI; X-ray; 2.00 A; A/B=1-350.
DR   PDB; 5Y9M; X-ray; 2.01 A; A/X=1-334.
DR   PDB; 5YF9; X-ray; 1.89 A; B/X=1-334.
DR   PDB; 5YWM; X-ray; 1.94 A; X=1-334.
DR   PDB; 6HMB; X-ray; 1.04 A; A=1-350.
DR   PDB; 6HMC; X-ray; 1.03 A; A=1-350.
DR   PDB; 6HMD; X-ray; 1.00 A; A=1-350.
DR   PDB; 6HMQ; X-ray; 0.97 A; A=1-346.
DR   PDB; 6L20; X-ray; 3.09 A; A/D/G/J=1-333.
DR   PDB; 6QY8; X-ray; 1.70 A; A/B/C/D=1-335.
DR   PDB; 6QY9; X-ray; 1.50 A; A=1-335.
DR   PDB; 6TE2; X-ray; 0.92 A; A=1-350.
DR   PDB; 6TEW; X-ray; 1.08 A; A=1-350.
DR   PDB; 6TGU; X-ray; 0.83 A; A=1-350.
DR   PDB; 7A1B; X-ray; 1.29 A; A=1-350.
DR   PDB; 7A1Z; X-ray; 1.02 A; A=1-350.
DR   PDB; 7A22; X-ray; 1.01 A; A=1-350.
DR   PDB; 7A2H; X-ray; 1.01 A; A=1-350.
DR   PDB; 7AT9; X-ray; 1.05 A; A=1-350.
DR   PDB; 7ATV; X-ray; 0.98 A; A=1-350.
DR   PDBsum; 3E3B; -.
DR   PDBsum; 3OFM; -.
DR   PDBsum; 3U87; -.
DR   PDBsum; 5M4U; -.
DR   PDBsum; 5M56; -.
DR   PDBsum; 5OOI; -.
DR   PDBsum; 5Y9M; -.
DR   PDBsum; 5YF9; -.
DR   PDBsum; 5YWM; -.
DR   PDBsum; 6HMB; -.
DR   PDBsum; 6HMC; -.
DR   PDBsum; 6HMD; -.
DR   PDBsum; 6HMQ; -.
DR   PDBsum; 6L20; -.
DR   PDBsum; 6QY8; -.
DR   PDBsum; 6QY9; -.
DR   PDBsum; 6TE2; -.
DR   PDBsum; 6TEW; -.
DR   PDBsum; 6TGU; -.
DR   PDBsum; 7A1B; -.
DR   PDBsum; 7A1Z; -.
DR   PDBsum; 7A22; -.
DR   PDBsum; 7A2H; -.
DR   PDBsum; 7AT9; -.
DR   PDBsum; 7ATV; -.
DR   AlphaFoldDB; P19784; -.
DR   SMR; P19784; -.
DR   BioGRID; 107842; 595.
DR   ComplexPortal; CPX-2428; Casein kinase II complex, CSNK2A2 variant.
DR   ComplexPortal; CPX-2437; Casein kinase II complex, CSNK2A1-CNSK2A2 variant.
DR   CORUM; P19784; -.
DR   DIP; DIP-318N; -.
DR   IntAct; P19784; 269.
DR   MINT; P19784; -.
DR   STRING; 9606.ENSP00000262506; -.
DR   BindingDB; P19784; -.
DR   ChEMBL; CHEMBL4070; -.
DR   DrugBank; DB07546; [1-(6-{6-[(1-methylethyl)amino]-1H-indazol-1-yl}pyrazin-2-yl)-1H-pyrrol-3-yl]acetic acid.
DR   DrugBank; DB12010; Fostamatinib.
DR   DrugCentral; P19784; -.
DR   GuidetoPHARMACOLOGY; 1550; -.
DR   GlyGen; P19784; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; P19784; -.
DR   MetOSite; P19784; -.
DR   PhosphoSitePlus; P19784; -.
DR   SwissPalm; P19784; -.
DR   BioMuta; CSNK2A2; -.
DR   DMDM; 125266; -.
DR   SWISS-2DPAGE; P19784; -.
DR   EPD; P19784; -.
DR   jPOST; P19784; -.
DR   MassIVE; P19784; -.
DR   MaxQB; P19784; -.
DR   PaxDb; P19784; -.
DR   PeptideAtlas; P19784; -.
DR   PRIDE; P19784; -.
DR   ProteomicsDB; 53686; -.
DR   Antibodypedia; 15225; 331 antibodies from 33 providers.
DR   DNASU; 1459; -.
DR   Ensembl; ENST00000262506.8; ENSP00000262506.3; ENSG00000070770.10.
DR   GeneID; 1459; -.
DR   KEGG; hsa:1459; -.
DR   MANE-Select; ENST00000262506.8; ENSP00000262506.3; NM_001896.4; NP_001887.1.
DR   UCSC; uc002enc.4; human.
DR   CTD; 1459; -.
DR   DisGeNET; 1459; -.
DR   GeneCards; CSNK2A2; -.
DR   HGNC; HGNC:2459; CSNK2A2.
DR   HPA; ENSG00000070770; Tissue enhanced (testis).
DR   MIM; 115442; gene.
DR   neXtProt; NX_P19784; -.
DR   OpenTargets; ENSG00000070770; -.
DR   PharmGKB; PA26959; -.
DR   VEuPathDB; HostDB:ENSG00000070770; -.
DR   eggNOG; KOG0668; Eukaryota.
DR   GeneTree; ENSGT00390000004215; -.
DR   OMA; NSKEKCI; -.
DR   OrthoDB; 1098380at2759; -.
DR   PhylomeDB; P19784; -.
DR   TreeFam; TF300483; -.
DR   BRENDA; 2.7.11.1; 2681.
DR   PathwayCommons; P19784; -.
DR   Reactome; R-HSA-1483191; Synthesis of PC.
DR   Reactome; R-HSA-201688; WNT mediated activation of DVL.
DR   Reactome; R-HSA-2514853; Condensation of Prometaphase Chromosomes.
DR   Reactome; R-HSA-445144; Signal transduction by L1.
DR   Reactome; R-HSA-6804756; Regulation of TP53 Activity through Phosphorylation.
DR   Reactome; R-HSA-6814122; Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding.
DR   Reactome; R-HSA-8934903; Receptor Mediated Mitophagy.
DR   Reactome; R-HSA-8939243; RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known.
DR   Reactome; R-HSA-8948751; Regulation of PTEN stability and activity.
DR   Reactome; R-HSA-9755511; KEAP1-NFE2L2 pathway.
DR   SignaLink; P19784; -.
DR   SIGNOR; P19784; -.
DR   BioGRID-ORCS; 1459; 19 hits in 1122 CRISPR screens.
DR   ChiTaRS; CSNK2A2; human.
DR   EvolutionaryTrace; P19784; -.
DR   GeneWiki; CSNK2A2; -.
DR   GenomeRNAi; 1459; -.
DR   Pharos; P19784; Tchem.
DR   PRO; PR:P19784; -.
DR   Proteomes; UP000005640; Chromosome 16.
DR   RNAct; P19784; protein.
DR   Bgee; ENSG00000070770; Expressed in secondary oocyte and 202 other tissues.
DR   ExpressionAtlas; P19784; baseline and differential.
DR   Genevisible; P19784; HS.
DR   GO; GO:0001669; C:acrosomal vesicle; IEA:Ensembl.
DR   GO; GO:0000785; C:chromatin; IEA:Ensembl.
DR   GO; GO:0005829; C:cytosol; IBA:GO_Central.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IEA:Ensembl.
DR   GO; GO:0005956; C:protein kinase CK2 complex; IBA:GO_Central.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0047485; F:protein N-terminus binding; IPI:UniProtKB.
DR   GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IGI:ARUK-UCL.
DR   GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW.
DR   GO; GO:0007049; P:cell cycle; IEA:UniProtKB-KW.
DR   GO; GO:0021987; P:cerebral cortex development; IEA:Ensembl.
DR   GO; GO:0097421; P:liver regeneration; IEA:Ensembl.
DR   GO; GO:2001234; P:negative regulation of apoptotic signaling pathway; TAS:ARUK-UCL.
DR   GO; GO:2000059; P:negative regulation of ubiquitin-dependent protein catabolic process; IGI:ARUK-UCL.
DR   GO; GO:0018105; P:peptidyl-serine phosphorylation; IDA:ARUK-UCL.
DR   GO; GO:0018107; P:peptidyl-threonine phosphorylation; IBA:GO_Central.
DR   GO; GO:1903955; P:positive regulation of protein targeting to mitochondrion; HMP:ParkinsonsUK-UCL.
DR   GO; GO:1903146; P:regulation of autophagy of mitochondrion; HMP:ParkinsonsUK-UCL.
DR   GO; GO:0051726; P:regulation of cell cycle; IBA:GO_Central.
DR   GO; GO:1905818; P:regulation of chromosome separation; IMP:UniProtKB.
DR   GO; GO:0007283; P:spermatogenesis; IEA:Ensembl.
DR   GO; GO:0016055; P:Wnt signaling pathway; IEA:UniProtKB-KW.
DR   CDD; cd14132; STKc_CK2_alpha; 1.
DR   InterPro; IPR045216; CK2_alpha.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   PANTHER; PTHR24054; PTHR24054; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Apoptosis; ATP-binding; Cell cycle; Cytoplasm;
KW   Kinase; Nucleotide-binding; Nucleus; Phosphoprotein; Reference proteome;
KW   Serine/threonine-protein kinase; Transcription; Transcription regulation;
KW   Transferase; Wnt signaling pathway.
FT   CHAIN           1..350
FT                   /note="Casein kinase II subunit alpha'"
FT                   /id="PRO_0000085891"
FT   DOMAIN          40..325
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   ACT_SITE        157
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10027"
FT   BINDING         46..54
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         69
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   MOD_RES         13
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0007744|PubMed:19369195"
FT   MOD_RES         18
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18691976,
FT                   ECO:0007744|PubMed:19369195, ECO:0007744|PubMed:23186163"
FT   MOD_RES         21
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18691976,
FT                   ECO:0007744|PubMed:19369195"
FT   MOD_RES         97
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         288
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18691976,
FT                   ECO:0007744|PubMed:19369195"
FT   VARIANT         188
FT                   /note="E -> A (in dbSNP:rs55911801)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040416"
FT   STRAND          11..13
FT                   /evidence="ECO:0007829|PDB:6TGU"
FT   TURN            14..19
FT                   /evidence="ECO:0007829|PDB:6TGU"
FT   HELIX           22..25
FT                   /evidence="ECO:0007829|PDB:6TGU"
FT   HELIX           27..29
FT                   /evidence="ECO:0007829|PDB:6TGU"
FT   STRAND          34..36
FT                   /evidence="ECO:0007829|PDB:6HMD"
FT   HELIX           37..39
FT                   /evidence="ECO:0007829|PDB:6TGU"
FT   STRAND          40..48
FT                   /evidence="ECO:0007829|PDB:6TGU"
FT   STRAND          50..59
FT                   /evidence="ECO:0007829|PDB:6TGU"
FT   TURN            60..62
FT                   /evidence="ECO:0007829|PDB:6TGU"
FT   STRAND          65..71
FT                   /evidence="ECO:0007829|PDB:6TGU"
FT   HELIX           76..88
FT                   /evidence="ECO:0007829|PDB:6TGU"
FT   TURN            89..91
FT                   /evidence="ECO:0007829|PDB:6TGU"
FT   STRAND          98..103
FT                   /evidence="ECO:0007829|PDB:6TGU"
FT   TURN            105..107
FT                   /evidence="ECO:0007829|PDB:6TGU"
FT   STRAND          110..115
FT                   /evidence="ECO:0007829|PDB:6TGU"
FT   HELIX           122..125
FT                   /evidence="ECO:0007829|PDB:6TGU"
FT   TURN            126..128
FT                   /evidence="ECO:0007829|PDB:6TGU"
FT   HELIX           131..150
FT                   /evidence="ECO:0007829|PDB:6TGU"
FT   HELIX           160..162
FT                   /evidence="ECO:0007829|PDB:6TGU"
FT   STRAND          163..166
FT                   /evidence="ECO:0007829|PDB:6TGU"
FT   TURN            167..170
FT                   /evidence="ECO:0007829|PDB:6TGU"
FT   STRAND          171..174
FT                   /evidence="ECO:0007829|PDB:6TGU"
FT   HELIX           177..179
FT                   /evidence="ECO:0007829|PDB:6TE2"
FT   HELIX           196..198
FT                   /evidence="ECO:0007829|PDB:6TGU"
FT   HELIX           201..204
FT                   /evidence="ECO:0007829|PDB:6TGU"
FT   HELIX           213..228
FT                   /evidence="ECO:0007829|PDB:6TGU"
FT   STRAND          231..234
FT                   /evidence="ECO:0007829|PDB:6TGU"
FT   HELIX           239..250
FT                   /evidence="ECO:0007829|PDB:6TGU"
FT   HELIX           252..262
FT                   /evidence="ECO:0007829|PDB:6TGU"
FT   HELIX           268..272
FT                   /evidence="ECO:0007829|PDB:6TGU"
FT   HELIX           282..285
FT                   /evidence="ECO:0007829|PDB:6TGU"
FT   TURN            288..290
FT                   /evidence="ECO:0007829|PDB:6TGU"
FT   HELIX           291..293
FT                   /evidence="ECO:0007829|PDB:6TGU"
FT   HELIX           296..305
FT                   /evidence="ECO:0007829|PDB:6TGU"
FT   HELIX           310..312
FT                   /evidence="ECO:0007829|PDB:6TGU"
FT   HELIX           316..320
FT                   /evidence="ECO:0007829|PDB:6TGU"
FT   HELIX           323..325
FT                   /evidence="ECO:0007829|PDB:6TGU"
FT   HELIX           326..332
FT                   /evidence="ECO:0007829|PDB:6TGU"
SQ   SEQUENCE   350 AA;  41213 MW;  3ECB92F6BD3DD7F1 CRC64;
     MPGPAAGSRA RVYAEVNSLR SREYWDYEAH VPSWGNQDDY QLVRKLGRGK YSEVFEAINI
     TNNERVVVKI LKPVKKKKIK REVKILENLR GGTNIIKLID TVKDPVSKTP ALVFEYINNT
     DFKQLYQILT DFDIRFYMYE LLKALDYCHS KGIMHRDVKP HNVMIDHQQK KLRLIDWGLA
     EFYHPAQEYN VRVASRYFKG PELLVDYQMY DYSLDMWSLG CMLASMIFRR EPFFHGQDNY
     DQLVRIAKVL GTEELYGYLK KYHIDLDPHF NDILGQHSRK RWENFIHSEN RHLVSPEALD
     LLDKLLRYDH QQRLTAKEAM EHPYFYPVVK EQSQPCADNA VLSSGLTAAR
//
